T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNSL
2326
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $379K | ﹤0.01% |
54,123
+484
| +0.9% | +$3.18K |
|
|
TBI
2327
Trueblue
TBI
$302M
| $378K | ﹤0.01% |
21,126
+69
| +0.3% | +$1.62K |
|
|
GAP
2328
The Gap Inc
GAP
$7.29B
| $378K | ﹤0.01% |
45,914
-127
| -0.3% | -$1.47K |
|
|
EPIX
2329
DELISTED
ESSA Pharma
EPIX
| $376K | ﹤0.01% |
119,451
| – | – |
|
2330
ACM Research
ACMR
$5.66B
| $375K | ﹤0.01% |
22,276
+6,976
| +46% | +$107K |
|
2331
Under Armour
UAA
$2.26B
| $374K | ﹤0.01% |
44,941
-215,647
| -83% | -$2.64M |
|
2332
Alight
ALIT
$377M
| $373K | ﹤0.01% |
2,765
+1,620
| +141% | +$266K |
|
2333
Coherus Oncology
CHRS
$181M
| $372K | ﹤0.01% |
51,329
+12,995
| +34% | +$113K |
|
2334
Uranium Energy
UEC
$5.62B
| $372K | ﹤0.01% |
120,911
+3,215
| +3% | +$13.4K |
|
2335
Mercer International
MERC
$32.3M
| $371K | ﹤0.01% |
28,225
| – | – |
|
|
RAD
2336
DELISTED
Rite Aid Corporation
RAD
| $371K | ﹤0.01% |
55,099
-178
| -0.3% | -$1.18K |
|
2337
AAR Corp
AIR
$5.96B
| $370K | ﹤0.01% |
8,836
+151
| +2% | +$7.05K |
|
2338
Anavex Life Sciences
AVXL
$316M
| $370K | ﹤0.01% |
36,961
+509
| +1% | +$4.82K |
|
2339
XPEL
XPEL
$1.35B
| $370K | ﹤0.01% |
8,054
+1,726
| +27% | +$81.5K |
|
|
PRSU
2340
Pursuit Attractions and Hospitality Inc
PRSU
$1.27B
| $370K | ﹤0.01% |
13,413
+185
| +1% | +$5.75K |
|
2341
Centrus Energy
LEU
$3.69B
| $368K | ﹤0.01% |
14,860
+6,026
| +68% | +$166K |
|
2342
First Community Bankshares
FCBC
$927M
| $367K | ﹤0.01% |
12,470
+3,068
| +33% | +$85.6K |
|
2343
Lexicon Pharmaceuticals
LXRX
$1.05B
| $367K | ﹤0.01% |
197,441
+43,509
| +28% | +$83K |
|
2344
Manitowoc
MTW
$727M
| $367K | ﹤0.01% |
34,835
+258
| +0.7% | +$3.23K |
|
2345
VEON
VEON
$3.92B
| $367K | ﹤0.01% |
31,928
| – | – |
|
2346
Customers Bancorp
CUBI
$2.8B
| $366K | ﹤0.01% |
10,783
+328
| +3% | +$13.3K |
|
2347
Harmony Biosciences
HRMY
$2.32B
| $366K | ﹤0.01% |
7,502
+437
| +6% | +$19.7K |
|
2348
Stem
STEM
$48.8M
| $366K | ﹤0.01% |
2,553
+944
| +59% | +$157K |
|
2349
KraneShares CSI China Internet ETF
KWEB
$5.31B
| $365K | ﹤0.01% |
+11,150
| New | +$320K |
|
2350
Editas Medicine
EDIT
$432M
| $364K | ﹤0.01% |
30,760
+5,758
| +23% | +$77.2K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.